Unfolding narratives, shaping futures

We're always working to initiate change for patients

This section includes information and helpful resources so you can stay up to date on the latest UroGen innovations, events, news coverage, and more.

UroGen® profile

UroGen is a biotech company dedicated to developing and commercializing innovative solutions that treat urological and specialty cancers because patients deserve better options. UroGen has developed a proprietary innovative technology platform, RTGel®, a reverse-thermal sustained-release hydrogel that has the potential to improve therapeutic profiles of existing drugs. UroGen’s sustained-release technology is designed to work with the urologic anatomy—not against it—enabling longer exposure of the urinary tract tissue to medications and making local therapy a potentially more effective treatment option.

Jelmyto® (mitomycin) for pyelocalyceal solution and investigational treatment UGN-102 (mitomycin) for intravesical solution for patients with low-grade intermediate risk non-muscle invasive bladder cancer, are designed to ablate tumors by nonsurgical means. UroGen is headquartered in Princeton, NJ with operations in Israel.

See our pipeline

Our leadership

See full leadership team

News releases

Jul 29, 2025

UroGen Pharma to Report Second Quarter 2025 Financial Results on Thursday, August 7th, 2025

Conference Call and Webcast Scheduled for Thursday, August 7 th , 2025, at 10:00 AM ET PRINCETON, N.J. , July 29, 2025 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty

Read story

Jul 28, 2025

UroGen Announces Publication of Phase 3b Study Results Demonstrating the Feasibility of Home Instillation of ZUSDURI™ for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer in Reviews in Urology

PRINCETON, N.J. , July 28, 2025 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative treatments for urothelial and specialty cancers, today announced the publication in Reviews in Urology of results from a Phase 3b study

Read story

Jul 21, 2025

UroGen Announces Five-Year Long-Term Extension Study of the OPTIMA II Trial Demonstrates Long-Term Durability of Response to ZUSDURI™ in Patients with Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer

Findings published in the journal of Clinical Genitourinary Cancer show patients remained event-free for a median of two years after achieving complete response with ZUSDURI (mitomycin) intravesical solution. Among the 17 patients who achieved complete response and entered a long-term extension

Read story

Events

Aug 7, 2025

UroGen Pharma Q2 2025 Earnings Call

Listen to webcast

Jun 13, 2025

UroGen Pharma ZUSDURI Approval Investor Call

Listen to webcast

May 28, 2025

TD Cowen: 6th Annual Oncology Innovation Summit: Insights for ASCO & EHA

Listen to webcast

May 12, 2025

UroGen Pharma Q1 2025 Earnings Call

Listen to webcast

Mar 10, 2025

UroGen Pharma Q4 2024 Earnings Call

Listen to webcast

Mar 3, 2025

TD Cowen 45th Annual Health Care Conference

Listen to webcast

Feb 20, 2025

Advancing Our Mission to Transform Cancer Care

Listen to webcast

Feb 11, 2025

Oppenheimer 35th Annual Healthcare Life Sciences Conference

Listen to webcast

Feb 5, 2025

Guggenheim Securities SMID Cap Biotech Conference

Listen to webcast

Nov 6, 2024

UroGen Pharma Q3 2024 Earnings Call

Listen to webcast
Connect with us
For more information about our products